SCHEMBL6118317

SCHEMBL6118317

Clc1cc(-c2ccccc2)cc(-c2ccccc2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.60
HSP90AA1 P07900 1/20 0.60
HSP90AB1 P08238 1/20 0.60
MEN1 O00255 5/20 0.59
KMT2A Q03164 5/20 0.59
ALDH1A1 P00352 2/20 0.59
HPGD P15428 2/20 0.59
L3MBTL1 Q9Y468 2/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
CYP19A1 P11511 1/20 0.50
MAPT P10636 3/20 0.48
TDP1 Q9NUW8 2/20 0.48
ADORA1 P30542 3/20 0.48
ADORA2A P29274 2/20 0.48
CTRC Q99895 1/20 0.47
ADORA3 P0DMS8 1/20 0.46
ADORA2B P29275 1/20 0.46
LMNA P02545 1/20 0.46
GABRA1 P14867 1/20 0.45
GABRG2 P18507 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26626435 0.98 KDM4E (0.58) KDM4EHSP90AA1HSP90AB1MEN1KMT2A
SCHEMBL30436540 0.94 KDM4E (0.55) KDM4EHSP90AA1HSP90AB1MEN1KMT2A
SCHEMBL20889210 0.94 KDM4E (0.55) KDM4EHSP90AA1HSP90AB1MEN1KMT2A
SCHEMBL20918236 0.92 CTRC (0.58) KDM4EHSP90AA1HSP90AB1MEN1KMT2A
SCHEMBL24212277 0.89 L3MBTL1 (0.53) KDM4EHSP90AA1HSP90AB1MEN1KMT2A
SCHEMBL28331410 0.86 KDM4E (0.47) KDM4EHSP90AA1HSP90AB1MEN1KMT2A
SCHEMBL4000527 0.86 KDM4E (0.52) KDM4EHSP90AA1HSP90AB1MEN1KMT2A
SCHEMBL20396108 0.84 CYP1A2 (0.52) KDM4EHSP90AA1HSP90AB1MEN1KMT2A
SCHEMBL30032338 0.84 KDM4E (0.49) KDM4EHSP90AA1HSP90AB1MEN1KMT2A
SCHEMBL960513 0.84 CYP19A1 (0.65) MEN1KMT2AALDH1A1HPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250324848-A1 LIGHT-EMITTING DEVICE, AND ELECTRONIC APPARATUS AND ELECTRONIC EQUIPMENT INCLUDING THE SAME SAMSUNG DISPLAY CO LTD (KR) 2025-10-16 US disclosed
US-20250212685-A1 LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE HETEROCYCLIC COMPOUND SAMSUNG DISPLAY CO., LTD. (KR) 2025-06-26 US disclosed
US-20250143170-A1 HETEROCYCLIC COMPOUND AND LIGHT-EMITTING DEVICE USING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2025-05-01 US disclosed
CN-119899208-A Heterocyclic compound, light-emitting device including the same, and electronic apparatus and electronic device including the light-emitting device 三星显示有限公司 2025-04-29 CN disclosed
US-11968897-B2 Heterocyclic compound and organic light emitting diode containing same LG CHEM, LTD. (KR) 2024-04-23 US disclosed
EP-3378853-B1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME LG CHEMICAL LTD (KR) 2024-04-17 EP disclosed
CN-112088158-B Compound and organic light emitting device comprising the same 株式会社LG化学 2024-03-08 CN disclosed
WO-2023160187-A1 CARBAZOLE DERIVATIVE AND USE THEREOF 上海八亿时空先进材料有限公司 2023-08-31 WO disclosed
US-11730009-B2 Compound and organic light-emitting element comprising same LG CHEM, LTD. 2023-08-15 US disclosed
US-11730009-B2 Compound and organic light-emitting element comprising same LG CHEM, LTD. 2023-08-15 US disclosed
US-5635197-A BENZO(F)QUINOLIN-3-ONES; ANTICARCINOGENIC AGENTS; BONE DISORDERS ELI LILLY AND COMPANY (US) 1997-06-03 US disclosed
US-5629007-A USING BENZOQUINOLIN-3-ONE DERIVATIVES ELI LILLY AND COMPANY (US) 1997-05-13 US disclosed
US-5622961-A PROSTATE CANCER, SKIN DISORDERS, BALDNESS ELI LILLY AND COMPANY (US) 1997-04-22 US disclosed
US-5622962-A PROSTATE CANCER, SKIN DISORDERS, BALDNESS ELI LILLY AND COMPANY (US) 1997-04-22 US disclosed
CN-1138458-A Treatment and prevention of prostatic cancer LILLY CO ELI (US) 1996-12-25 CN disclosed
US-5578724-A INHIBITORS OF 5-ALPHA-REDUCTASE ELI LILLY AND COMPANY (US) 1996-11-26 US disclosed
WO-1996035422-A1 METHODS FOR INHIBITING BONE LOSS ELI LILLY AND COMPANY (US) 1996-11-14 WO disclosed
EP-0742010-A2 Benzoquinolin-3-ones to inhibit bone loss ELI LILLY AND COMPANY (US) 1996-11-13 EP disclosed
EP-0733365-A2 Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer ELI LILLY AND COMPANY (US) 1996-09-25 EP disclosed
US-5550134-A ADMINISTERING TO A MAMMAL FROM A SERIES OF BENZOQUINOLIN-3-ONE COMPOUNDS ELI LILLY AND COMPANY (US) 1996-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250143170-A1 HETEROCYCLIC COMPOUND AND LIGHT-EMITTING DEVICE USING THE SAME CRY1, CYP1A1, NQO1 KDM4E 3637/4885HSP90AA1 3610/4885HSP90AB1 4199/4885
US-11730009-B2 Compound and organic light-emitting element comprising same CRY2, CRY1, NR2E3 KDM4E 1661/4885HSP90AA1 4778/4885HSP90AB1 4852/4885
US-11968897-B2 Heterocyclic compound and organic light emitting diode containing same CRY1, CCNT1, CYP1A1 KDM4E 2807/4885HSP90AA1 4615/4885HSP90AB1 4732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.